Sulphonylureas have been used for over 50 years to enhance insulin secretion in patients with Type II (non-insulin-dependent) diabetes mellitus but their therapeutic target was not discovered until 1985 and we are only just beginning to address their molecular mechanism of action. The sulphonylurea drugs were discovered serendipitously by Marcel Janbon in 1942, when he observed a high incidence of hypoglycaemic symptoms in typhoid patients treated with the bacteriostatic agent p-aminobenzenesulphamidoisopropylthiodiazole (2254RP) [1] . This observation was extended by Auguste Loubatires, who showed that 2254RP induced hypoglycaemia in dogs by stimulating insulin secretion [2] . Subsequently, it was discovered that another sulphonamide drug being tested for bacteriostatic effects, carbutamide, also caused hypoglycaemia in man [3] . Clinical studies followed and led to the development of tolbutamide for the treatment of Type II diabetes. The full story of these pioneering experiments has been vividly recounted in an earlier review by Henquin [4] . Numerous sulphonylureas and related compounds have now been synthesized, with different potencies and time-courses of action and many millions of Type II diabetic patients are now routinely treated with these drugs.
Introduction
Sulphonylureas have been used for over 50 years to enhance insulin secretion in patients with Type II (non-insulin-dependent) diabetes mellitus but their therapeutic target was not discovered until 1985 and we are only just beginning to address their molecular mechanism of action. The sulphonylurea drugs were discovered serendipitously by Marcel Janbon in 1942, when he observed a high incidence of hypoglycaemic symptoms in typhoid patients treated with the bacteriostatic agent p-aminobenzenesulphamidoisopropylthiodiazole (2254RP) [1] . This observation was extended by Auguste Loubatires, who showed that 2254RP induced hypoglycaemia in dogs by stimulating insulin secretion [2] . Subsequently, it was discovered that another sulphonamide drug being tested for bacteriostatic effects, carbutamide, also caused hypoglycaemia in man [3] . Clinical studies followed and led to the development of tolbutamide for the treatment of Type II diabetes. The full story of these pioneering experiments has been vividly recounted in an earlier review by Henquin [4] . Numerous sulphonylureas and related compounds have now been synthesized, with different potencies and time-courses of action and many millions of Type II diabetic patients are now routinely treated with these drugs.
The first clues to the mechanism of action of sulphonylureas on insulin secretion came with the discovery that these drugs depolarize the pancreatic beta cell and stimulate electrical activity [5] and the finding that this depolarization was due to a decrease in the potassium permeability of the beta-cell membrane [6] . Patch-clamp studies subsequently showed that sulphonylureas interact specifically with the ATP-sensitive potassium (K ATP ) channel in the betacell membrane and bring about its closure [7] . The activity of the K ATP channel sets the resting membrane potential of the unstimulated beta cell and its closure decreases the membrane K + permeability, producing membrane depolarization and insulin secretion [8] . Radioligand binding studies established the presence of both low-affinity and high-affinity sulphonylurea binding sites in the beta-cell membrane [9, 10] and led to considerable speculation about whether the high-affinity sulphonylurea receptor and the K ATP channel were the same or different proteins. The purification and subsequent cloning of a high-affinity sulphonylurea receptor from insulinoma cells [11] resolved this issue by showing that this receptor is an integral component of the K ATP channel [12, 13] .
In this article, we review the role of the K ATP channel in insulin secretion in health and disease. We also summarise current knowledge of how sulphonylureas act on the different types of K ATP channel found in beta cells and in extra-pancreatic tissues, and discuss the implications of these findings for the use of sulphonylureas as therapeutic agents to stimulate insulin secretion in humans. Finally, we consider the evidence for additional targets for sulphonylureas, both within the beta cell and in extra-pancreatic tissues.
pable of stimulating insulin secretion on their own and include nutrients, such as glucose, and drugs such as the sulphonylureas. All these substances act by inhibiting K ATP channel activity but whereas the nutrients must be metabolised to effect channel closure, the drugs bind directly to the channel and block its activity. Potentiators of insulin secretion include a number of hormones [for example, glucagon and glucagon-like peptide (GLP1)], transmitters (such as acetylcholine) and the amino acid arginine. These agents amplify insulin secretion induced by an initiator but cannot elicit insulin secretion by themselves because they do not close K ATP channels and are only able to exert their effects after an initiator secretagogue has effected K ATP channel inhibition. Inhibition of insulin release is produced by agents that open K ATP channels such as the drug diazoxide. Thus, the K ATP channel has a key role in the regulation of insulin secretion from the pancreatic beta cell [8] . Figure 1 illustrates the consensus model for stimulus-secretion coupling in the pancreatic beta cell. Insulin release is initiated by an increase of the intracellular Ca 2+ concentration, which is mediated by Ca 2+ influx through voltage-gated Ca 2+ channels in the plasma membrane. The opening and closing (gating) of these Ca 2+ channels is determined by the beta-cell membrane potential, which is in turn regulated by the activity of the K ATP channel. In the unstimulated beta cell, K ATP channels are open and the outward movement of K + ions through these channels holds the membrane potential at a negative level (-70 mV), at which voltage-gated Ca 2+ channels are closed. When the plasma glucose concentration rises, glucose uptake and metabolism by the pancreatic beta cell are enhanced and some product of glucose metabolism brings about the closure of the K ATP channels. This reduction in the membrane K + permeability causes the beta-cell membrane to depolarize (become less negative), because the outward flow of K + ions is now smaller than the background inward current. As a consequence of the change in membrane potential, the voltage-gated Ca 2+ channels open, allowing Ca 2+ influx and stimulating insulin release. The product of glucose metabolism that regulates K ATP channel activity remains controversial but, as discussed below, changes in the concentrations of adenine nucleotides may be involved.
Several classes of therapeutic drugs modulate insulin secretion by interacting directly with the K ATP channel [10, 14] . The most important of these are the sulphonylureas, which are used to enhance insulin secretion in patients with Type II diabetes mellitus. These drugs act by inhibiting the K ATP channel, thereby depolarizing the beta cell and stimulating Ca 2+ influx. In contrast to glucose, they interact directly with the channel to effect its closure. Another class of drugs are the K-channel openers. These comprise a structurally unrelated group of compounds that have the common property of opening K ATP channels. This leads to hyperpolarization of the beta cell and prevents insulin release, even in the presence of glucose. The most potent K ATP channel opener in the beta cell is diazoxide. Although diazoxide is occasionally used to inhibit insulin secretion in patients with inoperable insulinoma or persistent hypoglycaemic hyperinsulinaemia of infancy (PHHI), it has adverse side-effects including hirsutism and lowering of blood pressure.
It is clear from Figure 1 that any reduction in K ATP channel activity will enhance insulin secretion, whereas any increase in channel activity may be expected to decrease insulin release. It is therefore not surpri- Fig. 1 A, B . Model for insulin secretion. A resting. At low extracellular glucose levels (< 3 mmol/l), K ATP channels are open and their activity sets the resting potential of the pancreatic beta-cell at a hyperpolarised level of approximately ±70 mV. Diazoxide opens the K ATP channel, which hyperpolarises the beta cell and inhibits insulin secretion, even in the presence of glucose. B active. Glucose metabolism, possibly by changes in intracellular adenine nucleotide concentrations, induces K ATP channel closure. This leads to membrane depolarization, opening of voltage-gated Ca 2+ channels and an increase in cytosolic Ca 2+ that triggers the exocytosis of insulin. Sulphonylureas block the K ATP channel and initiate the same chain of events, even when glucose is absent
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sing that mutations in the K ATP channel which abolish or appreciably reduce its activity, result in the human disease PHHI, which is characterised by persistent insulin secretion in the face of very low blood glucose concentrations. In contrast, mutations in genes that compromise beta-cell metabolism and impair the ability of glucose to close the K ATP channel lead to certain forms of diabetes (MODY2 and MIDD). These diseases are discussed more fully below. The relative contributions of these effects remain to be established. The effect of PIP 2 on the ATP-sensitivity of the K ATP channel, however, is particularly dramatic and intracellular application of 5 mmol/l PIP 2 can reduce the half-maximum inhibitory concentration of ATP from approximately 10 mmol/l to more than 3 mmol/l within a few minutes [30] . The greater ATP-sensitivity observed in isolated membrane patches might therefore be explained by gradual washout of PIP 2 from the cell membrane following patch excision. It seems possible that the concentration of PIP 2 sets the resting ATP-sensitivity of the channel and accounts for the difference between the ATP-sensitivity observed in the excised patch and the intact cell. Whether or not changes in PIP 2 concentration contribute to the metabolic regulation of K ATP channel activity is still unclear.
The long-chain acyl-CoA ester, oleoyl CoA, is also able to activate K ATP channels [25±27] and reduce their sensitivity to ATP [28] . A threefold shift in ATP-sensitivity was found with 1 mmol/l oleoyl CoA. The relative potency of oleoyl CoA and PIP 2 is difficult to ascertain because the membrane concentration of the lipid will depend on its lipophilicity and on the duration of application. Their contributions to the resting ATP-sensitivity of the K ATP channel also remain to be established. Long-term exposure to non-esterified fatty acids (NEFAs), which occurs in obese subjects [32, 33] increases intracellular concentrations of LC acyl-CoA esters in the beta cell [25, 34] . This would be expected to activate K ATP channels, thereby tending to hyperpolarize the beta cell and inhibit insulin secretion. Thus it is possible that increased K ATP channel activity, induced by long-chain acyl-CoA esters, contributes to the impaired insulin secretion observed in obese Type II diabetic patients.
Mg-nucleotides, such as MgADP, also enhance K ATP channel activity and decrease its sensitivity to ATP [23, 24] . Nucleotide diphosphates such as MgADP and MgGDP are more potent in this respect than nucleotide triphosphates [35, 36] . Because ADP and ATP change reciprocally when glucose is metabolised, it was argued some time ago that changes in MgADP might contribute to the metabolic regulation of the channel [23, 24] . Recent studies of the cloned K ATP channel support this view. These have shown that mutations which abolish the ability of MgADP to activate the K ATP channel, also lead to the loss of metabolic regulation when the mutant channels are expressed in mammalian cells or Xenopus oocytes [37±39].
K ATP channels in other tissues K ATP channels are not only found in pancreatic betacells. They were first described in cardiac muscle [40] and then in beta cells [15] and subsequently have been found in a wide variety of other tissues, including smooth and skeletal muscle, brain neurones, peripheral axons and epithelial cells [10] . In all these tissues, they couple cell metabolism to membrane excitability and in some cases they mediate the actions of hormones and transmitters. In cardiac muscle they are involved in action potential shortening during ischaemia [41] , in vascular smooth muscle they regulate vessel tone [42] and in skeletal muscle they contribute to the enhanced K + efflux and fatigue found during severe exercise [43] . Their physiological role in neurones is not clearly established but it is believed that they regulate synaptic transmitter release [44] and that they might be involved in the response to cerebral ischaemia [45] .
K ATP channels in different tissues exhibit considerable variability in their sensitivity to K-channel openers [14, 46±48] . The beta-cell channel is activated by diazoxide, slightly activated by pinacidil and unaffected by cromakalim, nicorandil or minoxidil; cardiac and skeletal muscle K ATP channels are activated by pinacidil, cromakalim and nicorandil but not by di-azoxide; and smooth muscle K ATP channels are activated by diazoxide, cromakalim, pinacidil and nicorandil. Some differences have also been reported in the tissue specificity of sulphonylureas, as discussed more fully below.
The macroscopic (whole-cell) K ATP current is determined by the product of the number of channels in the cell membrane, the single-channel current and the percentage of time the channel stays open (the open probability). The single-channel conductance of both cardiac and beta-cell K ATP channels in symmetrical 140 mmol/l K + solutions lies between 55±80pS, depending on the temperature at which the recordings are made [8, 16, 40, 41, 143] . In smooth muscle, the reported single-channel conductance varies widely, suggesting that there might be more than one type of K ATP channel in this tissue [42] . Sulphonylureas and K-channel openers modulate the whole-cell current by influencing the channel open probability rather than the single-channel conductance.
A key question is to what extent K ATP channels are open under physiological conditions in tissues other than the beta cell, as this will determine whether or not sulphonylureas will have functional effects on extra-pancreatic tissues. In cardiac muscle, it is fairly clear that K ATP channels are normally closed and open only under conditions of severe metabolic stress [41] . In other tissues, however, their resting level of activity remains to be established. Another issue is whether the different metabolic sensitivities observed for cardiac and beta-cell K ATP channels result from differences in the metabolism of these tissues or are in the properties of the channels themselves.
Molecular identity of the K ATP channel
The K ATP channel is formed from two types of subunit: a pore-forming subunit, Kir6.x and a regulatory subunit, the sulphonylurea receptor (SUR), which coassembles with a 4: (Fig. 2) . There is no obvious consensus sequence for ATP-binding, although recent studies suggest that ATP interacts with this subunit to close the channel [58, 59] . The sulphonylurea receptors belong to the ABC-transporter superfamily [11] , which includes the cystic fibrosis gene product (CFTR) and the multidrug-resistance p-glycoprotein. These proteins are characterised by multiple transmembrane domains and two intracellular nucleotide-binding domains (NBDs) which contain consensus sequences for nucleotide binding and hydrolysis [60, 61] (Fig. 2) . SUR is thought to possess 17 TMs arranged in three groups of 5 + 6 + 6 [62, 63]. Fig. 2 A, Mutagenesis studies address the relation between K ATP channel structure and function. The question of which K ATP channel properties are endowed by Kir6.2 and which by SUR has been resolved by three types of experiments [68] . First, and most unequivocally, by the use of truncated forms of Kir6.2 which enable this subunit to form functional channels in the absence of a sulphonylurea receptor; secondly, by examining the properties of K ATP channels composed of different types of SUR subunit; and thirdly, by making site-directed mutations in either Kir6.2 or SUR.
Such studies have shown that the pore of the K ATP channel is formed from Kir6.2 subunits and that SUR does not influence the single-channel conductance or ion selectivity. To many people's surprise, Kir6.2 was also found to contain the primary site at which ATP acts to cause K ATP channel inhibition. This subunit is sensitive to ATP when expressed alone [58, 69, 70], shows reduced ATP-sensitivity when it is mutated [58, 71±73] and can be photo-affinity labelled with 8-azido-[
32 P]ATP [59] . The location of the binding site for ATP on Kir6.2 continues to remain elusive. It differs from most classical ATP-binding sites in that nucleotide binding does not require Mg 2+ [74] ; that the affinity for ADP is almost as high as that for ATP [71] ; and that it is highly selective for the adenine moiety (GTP, ITP, etc. are poor channel blockers) [71] . Thus it may constitute a novel class of ATP-binding site. It is thought that both oleoyl CoA and PIP 2 reduce the ATP-sensitivity of the K ATP channel by interaction with Kir6.2, since both agents are effective when this subunit is expressed in the absence of SUR [28, 29] . Two mechanisms have been put forward to explain this effect. First, PIP 2 and ATP might compete for the same, or overlapping, binding sites on Kir6.2. Secondly, the presence of negatively charged phospholipid in the membrane might reduce the local concentration of the negatively charged ATP molecule by electrostatic effects and thus cause an apparent reduction in ATP-affinity. Much work is currently devoted to resolving whether one, or both, of these explanations is correct.
The sulphonylurea receptor is very important for metabolic regulation of the K ATP channel as it confers sensitivity to the stimulatory effects of MgADP and MgGDP [35±39] . The effects of these nucleotides are mediated through interaction with the nucleotide-binding domains (NBDs) of SUR. The details of the mechanism have not yet been worked out but it seems that both NBDs are involved because mutation of a single NBD is sufficient to abolish the stimulatory effect of MgADP. This is consistent with functional studies of bacterial and eukaryotic ABC transporters [60, 75] . Nucleotide activation is dependent on the presence of Mg
2+
, does not discriminate between adenine, guanine or uridine nucleotides and MgADP is a more effective agonist than MgATP [36, 39] . In all these respects, the nucleotide-binding site of SUR differs from the ATP-binding site on Kir6.2.
Mutations in the NBDs that abolish the stimulatory effects of Mg-nucleotides also prevent K ATP channel activation by metabolic inhibition in intact cells [37, 38] . This argues that the SUR subunit, and its NBDs in particular, are critical for the metabolic regulation of the K ATP channel. It is perhaps worth emphasizing that these studies show that a key physiological role of SUR is to mediate the metabolic regulation of channel activity; it might be simply providential that SUR also binds sulphonylureas.
In summary, studies of cloned channels confirm that, as previously suspected [76, 77] , MgADP interacts with the K ATP channel at two sites, one that induces channel inhibition (now known to be on Kir6.2) and one that causes channel activation (on SUR). The overall action of MgADP, therefore, will be a balance between these two effects. Because ATP also interacts with both stimulatory and inhibitory sites [36, 58] , it is not a simple matter to work out the relative contributions of the adenine nucleotides to K ATP channel regulation in the intact beta cell.
In addition to mediating the stimulatory effects of MgADP, SUR endows the K ATP channel with several other properties. One finding is that SUR enhances the channel ATP-sensitivity, decreasing the K i for ATP inhibition of Kir6.2 from approximately 100 mmol/l to that found for the wild-type channel (~10 mmol/l) [58] . The mechanism involved has not yet been elucidated. The sulphonylurea receptor is also the principal target for pharmacological agents and confers high sensitivity both to sulphonylureas and to K + channel openers on Kir6.2. The mechanism of sulphonylurea action is discussed in more detail below: in this review, we do not consider how K-channel openers work because their molecular mechanism of action is less well understood.
Sulphonylurea action
The sulphonylurea receptor, as its name suggests, is the primary target for sulphonylureas. High-affinity binding sites for sulphonylureas were first identified in studies on rat brain and beta-cell tumours in the early 1980 s. Subsequently, extensive studies were carried out to characterise the properties of the binding sites for sulphonylureas in membranes isolated from beta cells, cardiac and smooth muscle. These studies (reviewed by [10] ), showed the presence of both high-affinity and low-affinity sites for sulphonylureas. The high-affinity beta-cell sulphonylurea receptor (SUR1) was purified and subsequently cloned by Aguilar-Bryan and her colleagues in a landmark paper published in 1995 [11] . The relative affinity of SUR1 for different sulphonylureas was identical to that found in native beta-cells [10] , with glibenclamide being much more potent than tolbutamide. Related sulphonylurea receptors were later cloned from heart (SUR2A), brain and smooth muscle (SUR2B) [53±55]. The cloned receptor SUR2A exhibits lower affinity for glibenclamide than SUR1 in binding studies, although both show approximately the same affinity in electrophysiological studies. Possible reasons for this difference are discussed below.
In addition to sulphonylureas, K ATP channels are blocked by a variety of benzoic acid derivatives (e. g. meglitinide) and by N-acylphenylalanine derivatives, such as A4166, which explains the ability of these compounds to enhance insulin secretion [78±80]. These drugs also interact with SUR1. The formulae of some of these non-sulphonylurea compounds, and of some of the most widely used sulphonylureas are given in Figure 3 .
How do sulphonylureas inhibit the K ATP channel? Studies of native beta-cell K ATP channels established that sulphonylureas inhibit the macroscopic (wholecell) K ATP current by reducing the channel open probability and that they have no effect on the single-channel conductance [97] . More recent studies of cloned K ATP channels have shed further light on the mechanism of action of sulphonylureas [81, 82] . It has become clear that these drugs interact with the K ATP channel at two sites: a low-affinity site that lies on Kir6.2 and a high-affinity site located on SUR1. Figure 4 illustrates the relation between tolbutamide concentration and inhibition of the cloned beta-cell type of K ATP channel (Kir6.2/SUR1) measured in the giant inside-out patch. This is best fit by a two-site model with an EC 50 of 2 mmol/l for the high-affinity site and of 2 mmol/l for the low-affinity site. For reasons that remain unclear, high-affinity inhibition blocks only about 60 % of the total current. One plausible explanation for this unexpected finding is that the K ATP channel exists in two states, only one of which is susceptible to tolbutamide inhibition. The picture is different in intact cells, where saturation of the high-affinity site does produce complete block of the channel. The reason this is the case is discussed more fully later.
The identity of the low-affinity sulphonylurea site was investigated by expressing a C-terminally truncated Kir6.2 (Kir6.2DC36) in the absence of the sulphonylurea receptor [81] . Inhibition of Kir6.2DC36 currents by sulphonylureas was found to be mediated by a single low-affinity site, with a K i of 1.7 mmol/l for tolbutamide and of 42 mmol/l for glibenclamide (Fig. 4) [82] . These values are the same as those obtained for the low-affinity site observed when Kir6.2 is coexpressed with SUR, confirming that the low-af- finity site resides on Kir6.2 and the high-affinity site on SUR1. The low-affinity site on Kir6.2 might not be the same as that identified in binding studies on native membranes, which could be associated with a different protein. Low-affinity block is unlikely to be of clinical relevance because plasma concentrations in diabetic patients do not reach such levels [83, 84] . The dose-response curves for sulphonylureas can, however, only be correctly interpreted when the lowaffinity block is taken into account.
Given that the K ATP channel is an octamer, containing 4 SUR subunits, the question arises as to the number of sulphonylurea molecules required to block the channel. This question remains to be answered.
Specificity of sulphonylurea action. A number of studies suggest that the different types of K ATP channel exhibit different specificities towards the various sulphonylureas. In particular, tolbutamide inhibits the beta cell (Kir6.2/SUR1) but not the cardiac (Kir6.2/ SUR2A) type of K ATP channel with high affinity (Fig. 5) . The low tolbutamide sensitivity of Kir6.2/ SUR2A currents is consistent with that reported for native cardiac K ATP channels (K i~1 mmol/l; ref [85, 143] ) and is similar to that found when Kir6.2DC36 is expressed in the absence of a sulphonylurea receptor (K i~2 mmol/l) [81] . Thus it appears that SUR2A, unlike SUR1, does not confer high-affinity tolbutamide inhibition on the K ATP channel. Gliclazide also appears to interact specifically with the beta-cell type of sulphonylurea receptor and not with that found in heart or smooth muscle [86] . Its affinity is greater than that of tolbutamide (K i = 50 nmol/l for gliclazide and~2 mmol/l for tolbutamide).
In contrast to tolbutamide, glibenclamide blocks both beta-cell and cardiac K ATP channels with high affinity (Fig. 5) . The K i s for Kir6.2/SUR1 and Kir6.2/ SUR2A currents were approximately 4 nmol/l and approximately 27 nmol/l, respectively [82] . Similar affinities are reported for native channels: the K i of the beta-cell channel is 4 nmol/l [87] , that of skeletal muscle is 6 nmol/l [48] and that of cardiac muscle is 7 nmol/l [88, 89]. One important difference, however, is that glibenclamide block of cardiac K ATP channels is readily reversible but inhibition of beta-cell K ATP channels is not reversible on the time scale of electro- Fig. 4 A, B. Tolbutamide interacts with two sites on the betacell K ATP channel, a high-affinity site on SUR1 and a low-affinity site of Kir6.2. A Effect of tolbutamide (0.1 mmol/l) on the beta-cell K ATP channel (Kir6.2/SUR1, left), and on the truncated Kir6.2 subunit (Kir6.2DC36) expressed in the absence of SUR (right) The decline in current amplitude observed in control solution is a characteristic feature of native and cloned K ATP channels. It is initiated following patch excision and the rate is very variable. The mechanism of channel rundown is still unclear but it is thought to reflect the time-dependent loss from the patch membrane of a substance that promotes channel activity. B Concentration-response relation for tolbutamide block of Kir6.2/SUR1 (left) and Kir6.2DC36 (right) currents. The conductance in the presence of the sulphonylurea is expressed as a fraction of that in the absence of the drug. Xenopus oocytes were coinjected with mRNAs encoding either Kir6.2 plus SUR1, or Kir6.2DC36, and macroscopic currents were recorded from inside-out patches in response to a series of voltage ramps from ±110 mV to + 100 mV. The data are taken from from ref . This slow dissociation may contribute to the long washout time observed when glibenclamide therapy is discontinued in patients.
Meglitinide is not a sulphonylurea but is a benzamido derivative, equivalent to the non-sulphonylurea moiety of glibenclamide (Fig. 3) . Like glibenclamide, meglitinide mediates high-affinity inhibition of native beta-cell K ATP channels and of both the cloned betacell and cardiac K ATP channel [78, 82, 87] . The affinity of this block is similar for the beta-cell and cardiac types of K ATP channel (K i s~0.3 mmol/l and 0.5 mmol/l, for Kir6.2/SUR1 and Kir6.2/SUR2A channels, respectively) and in both cases is readily reversible [82, 87]. These results have been interpreted to indicate that both SUR1 and SUR2A may possess a benzamido-binding site.
There are several possible explanations for why tolbutamide does not inhibit SUR2A currents with high affinity. Firstly, SUR2A may not possess a highaffinity tolbutamide binding site. Secondly, tolbutamide may bind to SUR2A with high-affinity but this binding may not result in channel closure. Current evidence favours the idea that although both SUR1 and SUR2A possess a`benzamido'-binding site, only SUR1 possesses a`sulphonylurea'-binding site (Fig. 6) [82]. Because glibenclamide contains both sulphonylurea and meglitinide moieties, it seems plausible that this drug binds to SUR1 at both the sulphonylurea and benzamido sites, but only interacts with a single (benzamido) site on SUR2A. This might account for the irreversible inhibition of Kir6.2/ SUR1 currents by glibenclamide, since simultaneous unbinding from both the sulphonylurea and benzamido sites is likely to occur with a low probability. By contrast, glibenclamide unbinding from SUR2A would occur more rapidly, since the drug need only dissociate from a single site. Likewise, tolbutamide and meglitinide, which also only interact with a single site, are readily reversible on both beta-cell and cardiac types of K ATP current. It is notable that earlier studies, carried out before the isolation of SUR, also led to the speculation that second generation sulphonylureas like glibenclamide interact with two sites in the beta-cell membrane [78, 91, 92] . Although similar studies have not yet been carried out to determine the specificity of other types of sulphonylurea, we suggest that drugs that show structural similarities to either glibenclamide or meglitinide may be expected to interact with both SUR1 and SUR2 whereas those that resemble tolbutamide and gliclazide in structure may interact specifically with SUR1.
Interaction between sulphonylureas and MgADP. Studies on native beta cells first showed a clear discrepancy between the inhibitory effect of sulphonylureas on whole-cell K ATP currents and those observed in excised membrane patches. Whereas 1 mmol/l tolbutamide was able to fully block the whole-cell current, complete inhibition was never observed in the excised patch [87, 97] . A similar anomaly is found for sulphonylurea inhibition of cloned beta-cell K ATP channels [56, 81] . Further analysis demonstrated that in intact cells, sulphonylureas inhibit channel activity by interaction with a single high-affinity site, but in inside out patches they interact with both high-affinity and low-affinity sites [81] . In excised patches, saturation of the high-affinity site produces only about 60 % block of the current, whereas it appears to completely block the current in the intact cell. This anomaly arises because the extent of sulphonylurea inhibition is modulated by MgADP, which is always present in the intact cell but not (unless deliberately added) in excised patches.
It has been known for many years that MgADP enhances the inhibitory effects of tolbutamide and meglitinide on native beta-cell K ATP channels [93, 94] . Similar findings have been observed for tolbutamide, meglitinide and glibenclamide on the cloned channel (Kir6.2/SUR1) [82] . The enhanced block does not reflect an increased binding affinity for sulphonylureas when MgADP is present: instead it results because sulphonylureas abolish the stimulatory action of MgADP mediated by SUR1, while leaving the inhibitory effect of the nucleotide on Kir6.2 intact [81]. Inhibition is thus due to the combined actions of MgADP and tolbutamide (Fig. 7) . Sulphonylureas might interfere with the potentiatory effects of Mgnucleotides either by reducing nucleotide binding or by preventing the translation of binding into channel activation. The former hypothesis is supported by the observation that glibenclamide is able to block the cooperative binding of MgATP and MgADP to SUR1 [95] .
In contrast to the beta-cell channel, MgADP does not potentiate the inhibitory effect of glibenclamide on either native or cloned cardiac K ATP channels (Kir6.2/SUR2A). Instead, low concentrations of MgADP apparently antagonise the effect of the sulphonylurea [82, 85, 96] , an effect which is dependent on the presence of Mg 2+ [96] . Thus in the presence of MgADP, the glibenclamide block is reduced. This explains why the sulphonylurea is far less effective on cardiac K ATP channels when measured in intact cells than in the inside-out patch. The mechanism underlying the reduced sensitivity of cardiac K ATP channels to sulphonylureas in the presence of MgADP is not Fig. 6 . Model for glibenclamide interaction with beta-cell and cardiac K ATP channels. K ATP channels containing the beta-cell sulphonylurea receptor, SUR1, have high-affinity sites for both sulphonylureas and benzamido compounds, whereas those containing the cardiac sulphonylurea receptor, SUR2A, have only the benzamido site. Because glibenclamide possesses both sulphonylureas and benzamido moieties it interacts with SUR1 at two sites, but only with a single site on SUR2A. Consequently, drug inhibition of Kir6.2/SUR1 currents reverses more slowly Fig. 7 A, B . Model for how MgADP causes an apparent enhancement of sulphonylurea block of the beta-cell K ATP channel. In the absence of sulphonylureas (A), MgADP interacts with Kir6.2 to cause channel inhibition and with SUR1 to potentiate channel activity: the resulting current is a balance between these two opposing effects. Tolbutamide prevents the stimulatory action of MgADP, unmasking the inhibitory effect of the nucleotide (B). In the presence of MgADP and tolbutamide, therefore, the block is the sum of the inhibitory effects of both agents and is greater than that observed when MgADP is absent
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known. Nevertheless, it has important clinical implications because it means that under physiological conditions sulphonylureas will be much less effective on cardiac K ATP channels than on those of beta cells. The converse effect of Mg-nucleotides on [ 3 H]-glibenclamide binding to beta-cell membranes has received considerable attention [10] . At concentrations of 0.5±1 mmol/l, both Mg-nucleotide diphosphates and triphosphates displace glibenclamide binding [90] . This may exert an additional influence on the sulphonylurea sensitivity of the K ATP channel when measured in intact cells.
Location of the sulphonylurea binding site. Sulphonylureas block the K ATP channel regardless of whether they are applied to the inside or the outside of the membrane [97, 98]: they are also effective in cellattached membrane patches when added to the bath solution. This suggests that sulphonylureas can reach their target site by diffusion through the membrane, a view supported by the fact that the undissociated, lipid-soluble form of the sulphonylurea is the effective species [99] .
Although the precise location of the sulphonylurea binding site has not been identified, there is increasing evidence that it may be located towards the inner membrane surface. This includes the observation that intracellular application of the proteolytic enzyme trypsin abolished 3 [H]-glibenclamide binding, whereas extracellular application of trypsin was without effect [100]. In addition, some sulphonylureas are more effective, or act more rapidly, when added to the inner side of the membrane than to the outside [101] . Mutagenesis studies are also consistent with an intracellular location for the tolbutamide binding site: for example, mutation of a single serine residue (S1237) which lies within the 8th intracellular loop of SUR1 abolished high-affinity tolbutamide inhibition [102] .
Because SUR1 is blocked by tolbutamide with high affinity whereas SUR2A is not, chimeras of these two subunits were used to identify regions of the protein involved in tolbutamide block [102] . It was found that high-affinity tolbutamide inhibition could be conferred on SUR2A by replacing TMs 13±16 with the corresponding region of SUR1 and conversely that high-affinity tolbutamide inhibition was abolished when the same region of SUR1 was replaced with the corresponding SUR2A sequence. Clearly, impairment of tolbutamide inhibition might reflect either a decrease in drug binding or a reduction in coupling of drug binding to channel inhibition. Since the affinity of tolbutamide is too low to enable it to be used in binding studies this issue cannot be addressed directly but additional studies favour the idea that TMs 13±16 constitute the actual binding site for tolbutamide [102] .
The first piece of evidence comes from the reversibility of glibenclamide action. Although both SUR1 and SUR2A are highly sensitive to glibenclamide, the block of Kir6.2/SUR2A currents is readily reversible whereas that of Kir6.2/SUR1 currents is not. Notably, transfer of tolbutamide sensitivity to SUR2A was accompanied by irreversible glibenclamide block, whereas loss of tolbutamide sensitivity in SUR1 was associated with reversible glibenclamide inhibition. The fact that tolbutamide inhibition and the irreversibility of glibenclamide block cosegregate suggests that the chimeras alter the binding properties of the channel and supports the idea that glibenclamide interacts with two parts of the SUR1 molecule (Fig. 6) .
Additional evidence that TMs 13±16 of SUR1 We therefore suggest that TMS13±16 of SUR1, and serine 1237 in particular, may form (part of) the tolbutamide-binding site. The location of the benzamino-binding site is still not known, and the fact that both SUR1 and SUR2A show similar sensitivity to this drug will make its identification a more difficult task.
Endogenous ligands for the sulphonylurea receptor. The high affinity with which sulphonylureas bind to SUR1 raised the question of whether an endogenous ligand for the K ATP channel exists that is able to mimic the inhibitory effects of sulphonylureas. The search for such an endogenous ligand led to the isolation and purification of a-endosulphine and b-endosulphine from porcine brain, two peptides which inhibit binding of sulphonylureas to their receptor in vitro [104] . Subsequently, human a-endosulphine was cloned [105] . It is 121 amino acids long and shows considerable sequence homology with a cyclic AMP-regulated phosphoprotein of unknown function called ARPP-19 [106, 107] . a-Endosulphine is expressed in a wide range of tissues including muscle, brain and endocrine tissues. It appears to be intracellular and not secreted, since it lacks the appropriate signal peptide. The recombinant protein displaces EC 50 of approximately 1 mmol/l, inhibits cloned betacell K ATP currents with the same affinity and stimulates insulin secretion in the absence of glucose [105] . Its functional relevance has not yet been established.
Relevance to sulphonylurea therapy in humans. The finding that some sulphonylureas display differential sensitivity towards the beta-cell, cardiac and smooth muscle types of K ATP channel inevitably raises the question of which sulphonylureas are of greatest therapeutic value in Type II diabetes.
A key issue in this regard is whether interaction of sulphonylureas with K ATP channels in extra-pancreatic tissues has any adverse effects. This question has been widely debated [108, 109] . The largest and most recent study, the UK prospective diabetes study, examined whether the incidence of microvascular and macrovascular complications in Type II diabetic patients subjected to intensive blood-glucose control is influenced by the type of therapy [110] . It found no difference in the mortality or diabetic end points of patients treated with insulin, glibenclamide or chlorpropamide. Since glibenclamide inhibits extrapancreatic K ATP channels with high affinity while chlorpropamide (which resembles tolbutamide in structure) is likely to show greater beta-cell specificity, this result suggests that if glibenclamide has any extra-pancreatic actions they do not influence mortality rates. We suggest that there may be several reasons why this is the case. First, cardiac K ATP channels are thought to be closed under physiological conditions and to open only in response to ischaemic stress [41]: obviously, glibenclamide will have no effect when the channel is already closed. Secondly, the efficacy of sulphonylureas is influenced by the metabolic state of the cell [82, 85] . In cardiac muscle, the metabolic inhibition that occurs during ischaemia will serve to decrease drug sensitivity. Thus, even at therapeutic concentrations the drug may not completely block ischaemic activation of K ATP channels. Thirdly, even if appreciable inhibition occurs, it may not influence cardiac mortality. Indeed, it remains unclear whether sulphonylureas are detrimental or actually beneficial in cardiac ischaemia.
In beta cells, the enhanced action of sulphonylureas in the presence of ADP [81, 93] suggests that the effect of the drug in vivo is not fixed but instead will vary with the metabolic state of the cell. The experimental results suggest that sulphonylureas would actually have greater activity when the metabolic rate is low, as is the case when plasma glucose is low. This might have the adverse effect of increasing insulin secretion still further during hypoglycaemia. The newer sulphonylureas and their derivatives which have short biological actions might be useful in circumventing this complication.
Whether or not sulphonylureas lose efficacy with extended use is currently a matter of some dispute [111] . In the light of this controversy, we will not consider the matter further here except to point out that although receptor down-regulation in the face of enhanced agonist concentrations is observed for many receptors, it is unlikely to account for any decline in sulphonylurea efficacy. This is because down-regulation of SUR1 would lead to a reduction in the number of K ATP channels and thus to enhanced insulin secretion.
Intracellular K ATP channels and sulphonylurea receptors
Sulphonylurea receptors and sulphonylurea-sensitive K ATP channels are not only found in the plasma membrane. They have also been reported in intracellular membranes such as those of mitochondria [112] and of the secretory granules of pancreatic acinar cells and pancreatic beta cells [113, 114] . The molecular identity of these sulphonylurea receptors and their putative pore-forming partners is still not clear. The mitochondrial K ATP channel has recently been purified and shown to consist of a 63 kDa sulphonylurea receptor (K d 60 nmol/l for glibenclamide) and a 55 kDa pore-forming subunit [115] but the sequences of these proteins are not yet available. A 65 kDa lowaffinity sulphonylurea receptor (K d 6 mmol/l for glibenclamide) has also been reported in pancreatic acinar cell zymogen granule membranes and may constitute a subunit of the K ATP channel in these membranes [116] . In beta cells, sulphonylureas have been shown to enhance insulin secretion by a direct effect on the secretory machinery [117] (although others have failed to reproduce these findings [118] ). It has been argued that this ability of sulphonylureas to modulate exocytosis is mediated by interaction with sulphonylurea receptors in the secretory granule membrane which exhibit high-affinity sulphonylurea binding [114] . It is important to emphasise, however, that the closure of K ATP channels in the plasma membrane is the primary mechanism of action of sulphonylureas; any effect on exocytosis will serve to amplify secretion, but not to initiate it.
Other actions of sulphonylureas
Extra-pancreatic effects of sulphonylureas include inhibition of gluconeogenesis in hepatocytes [119] and the stimulation of glucose uptake by muscle [120] and adipose tissue [121] . The drug concentrations required to achieve these effects are considerably higher than those required to block the beta-cell K ATP channel. For example, insulin-stimulated glucose transport in adipocytes was enhanced by glibenclamide with a K i of 2 mmol/l [121] , a sensitivity which is about 1000 times less than that for inhibition of the beta-cell K ATP channel. Furthermore, the pharmacology was not identical; meglitinide, for example, was ineffective on glucose transport and tolbutamide was almost as potent as glibenclamide (K i , 25 mmol/l). One possible explanation for the effects of sulphonylureas on insulin-stimulated glucose transport, therefore, is that SURs, or novel sulphonylurea receptors, are involved in insulin-dependent recruitment to the plasma membrane of vesicles containing the glucose transporter GLUT4. These extra-pancreatic actions of sulphonylureas are not thought, however, to be of clinical relevance [111, 144] .
Sulphonylureas are among the world's most important herbicides and stunt plant growth by inhibiting the enzyme acetolactate synthase, which is apparently absent in animals [122] . The effects of sulphonylurea herbicides on insulin secretion have not been documented in the literature.
Diseases of K ATP channel regulation
Persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI). Persistent hyperinsulinaemic hypoglycaemia of infancy is a rare recessively inherited disorder of glucose homeostasis which is characterised by unregulated insulin secretion and profound hypoglycaemia. Both familial and sporadic forms have been identified. Familial PHHI occurs at low frequency in most of northern Europe (~1 in 50 000) but in central Finland and Saudi Arabia the incidence can be as high as 1 in approximately 2700 live births. Affected patients present shortly after birth with severe hypoglycaemia, which is associated with sustained insulin secretion despite the low blood glucose concentration. Unless the disease is rapidly recognised and treated, the hypoglycaemia may cause irreversible brain damage. The disease is probably under-diagnosed and possibly contributes to the incidence of post-natal deaths from unknown causes.
Linkage analysis of families with PHHI indicated that the gene responsible maps to chromosome 11p14±15.1 [123] . Subsequently it was found that the genes for both K ATP channel subunits are clustered in the same region and more than 12 different mutations in SUR1, and 2 in Kir6.2 have now been reported to cause PHHI [124±128]. Mutations in SUR1 are the most common cause of the disease. These mutations occur throughout the protein. On the basis of their functional effects, we suggest that they may be grouped into two classes. Class I mutations result in the total loss of functional K ATP channel activity, even in excised membrane patches. These include the deletion of a phenylalanine at position 1388 (DF1388) and a V187N mutation found in the Finnish lineage [127, 128] . Class II mutations impair the ability of MgADP to enhance K ATP channel activity but do not change the inhibitory effect of ATP [38, 128] .
These mutations abolish the ability of the channel to respond to changes in metabolism and cause it to be permanently closed in the intact beta cell.
Both classes of PHHI mutations result in a lack of K ATP channel activity in the beta cell, even at low blood glucose concentrations. This results in a continuous depolarization of the beta cell and thereby a high resting intracellular Ca 2+ concentration [129] , which explains the constitutive insulin secretion characteristic of PHHI patients.
An animal model of PHHI. The physiological effects of the lack of K ATP channels have also been explored using an animal model in which the gene encoding Kir6.2 was disrupted [130] . When compared to control animals, beta cells isolated from homozygous Kir6.2 knockout mice had a more depolarized resting potential and a higher intracellular [Ca 2+ ] i concentration at rest, consistent with their lack of functional K ATP channels. Neither glucose nor tolbutamide elicited insulin secretion. Surprisingly, despite this defect in glucoseinduced insulin secretion, Kir6.2 knockout animals showed only mild impairment of glucose tolerance and their blood glucose concentrations were not different from those of normal animals. The fact that the ability of insulin to lower blood glucose concentrations was considerably enhanced in Kir6.2 knockout animals could account for this effect. This would also be consistent with a putative role for K ATP channels in extra-pancreatic tissues, as discussed above.
Diabetes. Although the aetiology of Type II diabetes mellitus is still obscure, there is evidence that the disease is associated with defective beta-cell secretion. One possible reason for the loss of glucose sensitivity would be a failure of metabolism to cause closure of the K ATP channel, either because of a defect in the channel itself or in its regulation. The former does not appear to be a major cause of Type II diabetes because no mutations in Kir6.2 or in SUR1 associated with Type II diabetes have been detected, despite extensive screening of several populations across different ethnic groups [131±134]. One explanation for this finding may be that such mutations are lethal. A mutation that results in decreased insulin secretion is most likely to be caused by a reduction in the ATPsensitivity of the K ATP channel, and thus to occur in Kir6.2. Since Kir6.2 serves as the pore-forming subunit in many other tissues including heart, brain and smooth muscle, mutations that lead to reduced ATPsensitivity and increased K ATP channel activity can be expected to have extra-pancreatic actions. These could have adverse effects, as exemplified by the high incidence of ventricular fibrillation observed when guinea-pig hearts are treated with the K + channel opener pinacidil [135] .
It remains possible, however, that defective metabolic regulation of K ATP channels might be involved in the aetiology of Type II diabetes. Defective metabolic regulation of K ATP channels is actually observed in two rare types of diabetes. Maturity-onset diabetes of the young (MODY2) results from mutations in glucokinase, the enzyme which catalyses the first step in glucose metabolism (the conversion of glucose to glucose-6-phosphate) in liver and beta cells [136±138] . In French families, around 80 % of all MODY patients show linkage of the disease to the glucokinase gene [139] . Maturity onset diabetes of the young Type 2 shows autosomal dominant inheritance and all patients identified to date are heterozygotes. They exhibit mild hyperglycaemia with fasting blood glucose concentrations of approximately 7 mmol/l. Mice in which the glucokinase gene has been disrupted (knocked-out) specifically in the beta-cell, develop severe hyperglycaemia and die within 3 days of birth whereas heterozygous animals show symptoms resembling those of MODY2 patients [140] . Because expression of glucokinase in the liver was not affected in these knockout mice, it appears that a beta-cell defect is sufficient to explain the MODY2 phenotype. There was an almost total loss of glucose sensitivity of the beta-cell K ATP channel in homozygous mice and a reduction in heterozygotes, which results from impaired glycolytic metabolism [141] . Defective regulation of K ATP channels probably also accounts for the reduction in glucosestimulated insulin release in MODY2 patients.
Impaired mitochondrial metabolism can also give rise to diabetes. Maternally-inherited diabetes with deafness (MIDD) results from a mutation at position 3243 of the mitochondrial DNA, which encodes a leucine transfer RNA [142] . It seems likely that the failure of insulin secretion in MIDD patients results because glucose metabolism is impaired and fails to cause closure of the K ATP channel.
Conclusions
The K ATP channel sits at the heart of the stimulus-secretion coupling pathway in the pancreatic beta-cell. Nutrient secretagogues, like glucose, evoke K ATP channel closure as do the sulphonylurea drugs that are used by millions of diabetic patients every day. Because the K ATP channel controls the membrane potential of the beta-cell its inhibition leads to membrane depolarization and an activation of Ca 2+ influx that stimulates insulin secretion.
During the past few years, there has been rapid progress in understanding the relation between the structure and function of the K ATP channel. We now know that it consists of two subunits with distinct functions, and that different kinds of K ATP channel arise by association of different types of subunit. Although the way in which the channel is modulated by metabolism continues to remain elusive, the molecular mechanism of action of sulphonylureas is beginning to be unravelled. Contrary to previous assumptions, it appears that some sulphonylureas exhibit differential sensitivity to beta cell and extrapancreatic K ATP channels. The clinical relevance of this finding is probably small but it is certain to generate some debate about the choice of sulphonylurea for diabetes therapy.
The importance of the K ATP channel for insulin secretion is clearly exemplified by the recent findings that mutations (in either subunit) that abolish channel activity produce the persistent insulin secretion that characterises PHHI whereas defects in the metabolic regulation of the channel cause MODY2 or MIDD by enhancing channel activity and so inhibit insulin secretion. Although mutations in the K ATP channel itself are not a major cause of Type II diabetes, a question that remains largely unexplored is to what extent impaired beta-cell metabolism, and consequent defective regulation of K ATP channel activity, is involved in the aetiology of the disease. 
